Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Local Pressure Shores Up Drug Firms (India)

This article was originally published in PharmAsia News

Executive Summary

Estimates released by global investment giant Goldman Sachs project India will be the world's fifth-largest market for pharmaceuticals by 2020. According to the analysis, companies who have already established themselves in Indian will see the biggest returns as a result of this growth. Sun Pharmaceuticals and Nicholas Piramal were cited as two drug-makers with the best prospects to mine India's soon-to-be booming market. In fact, Nicolas Piramal has recently upped its sales force in the country to 3,300 and its pipeline now covers nine therapies. Another corporation looking to cash-in on India's future drug market is Glenmark. The company already boasts an extensive drug portfolio as well as a sales team with 1,900 representatives. Goldman Sachs said the steep increase in drug sales would come as a result of the country's high rates of urbanization and the proliferation of chronic "lifestyle" diseases. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts